"At-Home" Photobiomodulation: A New Approach for Bell's Palsy Treatment

Efficacy of photobiomodulation therapy on Bell's palsy symptoms: a systematic review

Bell's palsy, characterized by sudden facial paralysis, affects a significant proportion of the population annually, yet its exact cause remains elusive. Recently, increasing attention has been directed towards photobiomodulation therapy (PBMT) and its prospective contribution to managing various neurological and musculoskeletal conditions, including Bell's palsy. A systematic literature search of different databases was performed using a specific search strategy to find eligible studies that evaluated the potential of PBMT in managing Bell's palsy, considering its non-invasive nature and tissue healing properties. Data extraction was done based on inclusion and exclusion criteria. The systematic review included studies published from 1993 to 2022, examining the effects of photobiomodulation therapy on Bell's palsy. The studies, involving 21 to 120 participants aged 18 to 70, utilized various PBMT parameters such as wavelengths (830-850 nm and 808/905 nm), energy densities (8-20 J/cm²), and irradiation times (10-125 s). The results demonstrated significant improvements in facial muscle function, pain intensity, and muscle strength, showing that PBMT is effective in enhancing facial nerve function recovery in Bell's palsy patients. Statistical analysis showed that PBMT treatments had significant improvements compared to control groups (p < 0.05). Our systematic review indicates that photobiomodulation therapy can improve facial muscle function, pain intensity, and muscle strength in Bell's palsy patients. Notably, wavelengths of 830-850 nm and the combination of 808/905 nm yielded the most favorable results. However, due to heterogeneity in study designs, PBMT parameters, and outcome measures, further standardized and well-designed randomized controlled trials are necessary to establish optimal treatment protocols and validate these findings comprehensively.

Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial

To investigate the efficacy of laser acupuncture and photobiomodulation therapy in alleviating symptoms among patients diagnosed with Bell's palsy with duration of greater than 8 weeks. The randomized controlled trial has been performed from May 2021 to April 2023. Patients were eligible who had Bell's palsy with duration of greater than 8 weeks on out-patient Department of Otorhinolaryngology in Beijing Tongren Hospital. The laser acupuncture group received class IV laser treatment for 3 times per weeks, a total of 72 times. The control group received the same treatment procedure except the laser parameter. The primary outcome measures comprised House-Brackmann facial nerve grading system and electroneurography. Secondary outcome measures comprised Sunnybrook facial grading system, electromyography, and the blink reflex. A total of 84 participants were included (42 control group, 42 laser acupuncture group). After treatment, House-Brackmann facial nerve grading system (OR, 0.11; 95% CI, 0.04-0.30; P < 0.001), and the pathologic numbers of electroneuronography were statistically different between the laser acupuncture group and control group, including orbicularis oculi (OR,0.08; 95% CI, 0.02-0.21; P < 0.001), Frontalis muscle (OR,0.14; 95% CI, 0.05-0.39; P < 0.001), Orbicularis oris (OR,0.13; 95% CI, 0.04-0.36; P < 0.001), Ala nasi muscle (OR,0.06; 95% CI, 0.02-0.18; P < 0.001). In secondary outcomes, Sunnybrook facial grading system, has significant difference between the two groups (20.26; 95% CI, 14.69 to 25.83; P < 0.01). Latency by ENoG, include orbicularis oculi (-0.61; 95% CI, -0.43 to -0.09; P < 0.001), frontalis muscle (-0.12; 95% CI, -0.21 to -0.03; P < 0.01), orbicularis oris (-0.28; 95% CI, -0.41 to -0.16; P < 0.001), and ala nasi muscle (-0.26; 95% CI, -0.38 to -0.16; P < 0.001). All amplitudes of MUAPs and durations by electromyography (EMG) showed statistically significant differences compared with the control group after treatment. For the frontalis muscle, the amplitude of MUAPs was -64.23 (95% CI, -80.89 to -47.56; P < 0.001) and duration was -1.18 (95% CI, -1.49 to -0.87; P < 0.001). For orbicularis oris, amplitude of MUAPs was -29.82 (95% CI, -55.03 to -4.62; P = 0.02) and duration was -0.57 (95% CI, -0.94 to -0.20; P < 0.001). For depressor angulli oris, amplitude of MUAPs was -47.06 (95% CI, -62.15 to -31.97; P < 0.001) and duration was -2.21 (95% CI, -2.69 to -1.72; P < 0.001). Blink reflex, including R1 (OR, 0.03; 95% CI, 0.01-0.16; P < .001), R2 (OR, 0.04; 95% CI, 0.004-0.29; P < .001), and R2 latency differences (OR, 0.15; 95% CI, 0.05-0.51; P < .001), have significant difference between the two groups, respectively. The findings suggest that laser acupuncture relieve symptoms for patients with Bell's palsy with a duration of greater than 8 weeks.Trial registration: ClinicalTrials.gov Identifier: NCT05846217.